Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder — READ-ADHD

Adult Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:
Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder - a Randomized Controlled Trial

Status Active, not recruiting

Clinical Trial Summary

In this randomized controlled clinical trial, 326 patients with ADHD will be investigated regarding the effectiveness of a digital therapeutic for improved ADHD symptomatology, the unguided online intervention attexis. Inclusion criteria are: male, female or non-binary, age 18-65, diagnosis of ADHD, elevated levels of ADHD symptoms (score of ≥17 either on the inattention subscale or on the impulsivity/hyperactivity subscale of the ASRS v1.1), stable treatment for at least 30 days at time of inclusion, sufficient German skills, and consent to participation. Exclusion criteria are: Diagnosis of any other severe psychiatric disorder and plans to change treatment in the upcoming three months. Patients will be randomized and allocated to either an intervention group, receiving access to attexis in addition to TAU, or a control group, receiving access to TAU only. Primary endpoint will be self-rated ADHD symptomatology, assessed via the ASRS v1.1, with three months post-allocation being the primary time point for assessment of effectiveness. Six months post allocation will be used as a timepoint for follow-up assessment of endpoints. Secondary endpoints will be depressive symptoms, self-esteem, work and social functioning, and health-related quality of life.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adult Attention Deficit Hyperactivity Disorder
Attention Deficit Disorder with Hyperactivity
Hyperkinesis

Clinical Trial Details

NCT number	NCT06221930
Study type	Interventional
Source	Gaia AG
Contact
Status	Active, not recruiting
Phase	N/A
Start date	March 4, 2024
Completion date	March 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06000501` - Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening	Phase 4
Completed	`NCT03721588` - Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
Completed	`NCT03324581` - The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder	Phase 2
Completed	`NCT02160262` - Open-label Safety Study in Adults With ADHD	Phase 3
Completed	`NCT02276209` - Dasotraline Adult ADHD Study	Phase 3
Completed	`NCT01798381` - Essential Fatty Acids in Adult ADHD	Phase 3
Completed	`NCT01692782` - Adult Attention Deficit Hyperactivity Disorder	Phase 2
Completed	`NCT00553319` - Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence	Phase 2/Phase 3